LncRNA ROR modulates myocardial ischemia-reperfusion injury mediated by the miR-185-5p/CDK6 axis

Jing Sun1, Yan-Meng Zhu2, Qin Liu1

  • 1Department of Anesthesiology, Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, P.R. China.

Insights

The ROR/miR-185-5p/CDK6 pathway regulates pyroptosis and inflammation in myocardial ischemia-reperfusion injury (MIRI). Targeting this axis may offer new therapeutic strategies for MIRI.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Cellular Pathophysiology

Background:

  • Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) are implicated in myocardial ischemia-reperfusion injury (MIRI).
  • The specific roles of lncRNA ROR and miR-185-5p in MIRI pathogenesis remain largely undetermined.

Purpose of the Study:

  • To investigate the involvement of lncRNA ROR and miR-185-5p in hypoxia/reoxygenation (H/R)-induced injury in human cardiac myocytes (HCMs).
  • To elucidate the regulatory axis ROR/miR-185-5p/CDK6 in MIRI and its impact on pyroptosis and inflammation.

Main Methods:

  • In vitro models using human cardiac myocytes (HCMs) subjected to hypoxia/reoxygenation (H/R).
  • In vivo Wistar rat model of ischemia-reperfusion (I/R) injury.
  • Quantitative real-time PCR (qRT-PCR), ELISA, Western blotting, and dual-luciferase reporter assays were employed to assess molecular changes and interactions.

Main Results:

  • H/R treatment decreased miR-185-5p expression while increasing ROR and CDK6 expression in HCMs.
  • Knockdown of ROR reduced H/R-induced pyroptosis and inflammation; miR-185-5p knockdown exacerbated these effects.
  • The ROR/miR-185-5p/CDK6 axis was identified, where ROR negatively regulates miR-185-5p, which in turn targets CDK6, modulating pyroptosis and inflammation.

Conclusions:

  • The ROR/miR-185-5p/CDK6 axis plays a critical role in mediating H/R-induced pyroptosis and inflammation in cardiac myocytes.
  • Targeting the ROR/miR-185-5p/CDK6 pathway presents a potential therapeutic avenue for mitigating myocardial ischemia-reperfusion injury.